Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Clasificación en acciones #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Precio por acción
$0.00047446
Capitalización bursátil
$82.80
Cambio (1 día)
0.00%
Cambio (1 año)
-98.16%
País
FR
Comercio Neovacs S.A. (ALNEV)

Categoría

Historial de dividendos de Neovacs S.A. (ALNEV)
Neovacs S.A. (símbolo bursátil: ALNEV) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Neovacs S.A. (ALNEV) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
52.00%
DK
0.00%
US
5.00%
US
29.00%
BE
0.00%
NL